Curaleaf Holdings, Inc.

TSX:CURA Voorraadrapport

Marktkapitalisatie: CA$3.1b

Curaleaf Holdings Beheer

Beheer criteriumcontroles 2/4

De CEO Curaleaf Holdings is Boris Jordan, benoemd in Aug2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.35M, bestaande uit 6.1% salaris en 93.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 17.37% van de aandelen van het bedrijf, ter waarde CA$ 533.83M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 5.4 jaar.

Belangrijke informatie

Boris Jordan

Algemeen directeur

US$12.4m

Totale compensatie

Percentage CEO-salaris6.1%
Dienstverband CEOless than a year
Eigendom CEO17.4%
Management gemiddelde ambtstermijn2.3yrs
Gemiddelde ambtstermijn bestuur5.4yrs

Recente managementupdates

Recent updates

Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

Aug 13
Curaleaf Holdings, Inc. (TSE:CURA) Shares Slammed 25% But Getting In Cheap Might Be Difficult Regardless

These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively

Jul 19
These 4 Measures Indicate That Curaleaf Holdings (TSE:CURA) Is Using Debt Extensively

Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%

Jun 14
Some Confidence Is Lacking In Curaleaf Holdings, Inc. (TSE:CURA) As Shares Slide 27%

Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Jan 19
Subdued Growth No Barrier To Curaleaf Holdings, Inc. (TSE:CURA) With Shares Advancing 25%

Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?

Dec 11
Does Curaleaf Holdings (CSE:CURA) Have A Healthy Balance Sheet?

Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?

Sep 08
Is Curaleaf Holdings (CSE:CURA) Using Too Much Debt?

Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?

May 28
Curaleaf Holdings (CSE:CURA) Has Debt But No Earnings; Should You Worry?

We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt

Sep 05
We Think Curaleaf Holdings (CSE:CURA) Is Taking Some Risk With Its Debt

Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden

May 20
Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden

Is Curaleaf Holdings (CSE:CURA) A Risky Investment?

Oct 26
Is Curaleaf Holdings (CSE:CURA) A Risky Investment?

Loss-Making Curaleaf Holdings, Inc. (CSE:CURA) Set To Breakeven

Mar 20
Loss-Making Curaleaf Holdings, Inc. (CSE:CURA) Set To Breakeven

Analyse CEO-vergoeding

Hoe is Boris Jordan's beloning veranderd ten opzichte van Curaleaf Holdings's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$221m

Mar 31 2024n/an/a

-US$237m

Dec 31 2023US$12mUS$750k

-US$230m

Sep 30 2023n/an/a

-US$349m

Jun 30 2023n/an/a

-US$318m

Mar 31 2023n/an/a

-US$268m

Dec 31 2022US$3mUS$750k

-US$258m

Sep 30 2022n/an/a

-US$157m

Jun 30 2022n/an/a

-US$202m

Mar 31 2022n/an/a

-US$223m

Dec 31 2021US$3mUS$750k

-US$206m

Sep 30 2021n/an/a

-US$164m

Jun 30 2021n/an/a

-US$90m

Mar 31 2021n/an/a

-US$57m

Dec 31 2020US$2mUS$500k

-US$57m

Sep 30 2020n/an/a

-US$52m

Jun 30 2020n/an/a

-US$50m

Mar 31 2020n/an/a

-US$72m

Dec 31 2019US$750kUS$500k

-US$67m

Sep 30 2019n/an/a

-US$57m

Jun 30 2019n/an/a

-US$84m

Mar 31 2019n/an/a

-US$64m

Dec 31 2018US$2mUS$500k

-US$56m

Sep 30 2018n/an/a

-US$40m

Jun 30 2018n/an/a

-US$6m

Mar 31 2018n/an/a

-US$3m

Dec 31 2017US$94kn/a

-US$3m

Compensatie versus markt: De totale vergoeding ($USD 12.35M ) Boris } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 2.06M ).

Compensatie versus inkomsten: De vergoeding van Boris is gestegen terwijl het bedrijf verliesgevend is.

CEO

Boris Jordan (58 yo)

less than a year

Tenure

US$12,352,753

Compensatie

Mr. Boris Alexis Jordan is Executive Chairman of the Board at Curaleaf, Inc. and serves as its CEO since 2024. He is Owner and Chief Investment Officer of Closed End Strategies of Measure 8 Ventures Manage...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Boris Jordan
CEO & Chairmanless than a yearUS$12.35m17.37%
CA$ 533.8m
Joseph Lusardi
Executive Vice-Chairman6.1yrsUS$1.23m0.71%
CA$ 21.8m
Edward Kremer
Chief Financial Officer2.3yrsUS$2.76m0.033%
CA$ 1.0m
Peter Clateman
Chief Legal Officer4.7yrsUS$1.39m0.11%
CA$ 3.3m
Matthew Darin
Special Advisorless than a yearUS$5.18m0.57%
CA$ 17.6m
Camilo Lyon
Chief Investment Officer2.3yrsgeen gegevensgeen gegevens
Christine Taylor
Chief Accounting Officerless than a yeargeen gegevensgeen gegevens
Jakob Feinstein
Manager of Investor Relationsno datageen gegevensgeen gegevens
James Shorris
Chief Compliance Officer4.7yrsgeen gegevensgeen gegevens
Kate Lynch
Executive Vice President of Marketing3.8yrsgeen gegevensgeen gegevens

2.3yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CURA wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Boris Jordan
CEO & Chairman6.1yrsUS$12.35m17.37%
CA$ 533.8m
Joseph Lusardi
Executive Vice-Chairman6.1yrsUS$1.23m0.71%
CA$ 21.8m
Mitchell Kahn
Director4.3yrsUS$250.00k0.046%
CA$ 1.4m
Peter Derby
Independent Director6.1yrsUS$350.00k0.075%
CA$ 2.3m
Karl Johansson
Independent Director6.1yrsUS$350.00k0.019%
CA$ 581.7k
Robert Schnoll
Member of the Medical Advisory Boardno datageen gegevensgeen gegevens
Jaswinder Grover
Independent Director4.8yrsUS$250.00k0.74%
CA$ 22.9m
Michelle Bodner
Director1.9yrsUS$250.00k0.039%
CA$ 1.2m
Shasheen Shah
Independent Director1.9yrsUS$250.00k0.0089%
CA$ 272.9k

5.4yrs

Gemiddelde duur

60.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CURA wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).